Daiwon Pharmaceutical's First-Half Operating Profit Falls 45%, Cites R&D and Marketing Costs

Daiwon Pharmaceutical's profitability has declined significantly in the first half of the year, with operating profit dropping by 45.3% to 4.4 billion won. This decrease occurred despite a 3.1% rise in sales, which reached 310.9 billion won compared to the same period last year.

The company attributed the dip in earnings to increased investments in research and development (R&D) and marketing activities. These strategic expenditures, aimed at future growth and product development, have impacted the short-term profitability figures.

However, Daiwon Pharmaceutical experienced robust sales in specific sectors. The company reported strong performance in its chronic disease treatment medications and health functional foods. These areas contributed positively to the overall revenue growth, indicating sustained demand for its healthcare products.

The net profit also saw a reduction, partly influenced by the gains from the disposal of investment assets. The company's financial report highlights a strategic shift towards investing more in R&D and marketing, suggesting a focus on long-term expansion and market competitiveness.